Published date: 5 October 2021

This notice was replaced on 5 October 2021

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Early engagement (published 5 October 2021, last edited 9 December 2021)

Closed early engagement


Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

SW1H 0EU

Procurement reference

CF-0367000D0O000000rwimUAA1

Published date

5 October 2021

Closing date

31 March 2022

Contract type

Supply contract

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

DHSC invites suppliers to submit an EOI on neutralising antibodies and
binding site, clinical trials on efficacy, safety
for preventing or treating COVID-19
infection, dose&frequency, formats/routes
for administering to patients, monitoring
adverse affects, efficacy against SARSCoV-
2 variants, supply availability for 2021-
2022 and future years and plans for
regulatory approval in the UK, if not yet
approved

About the buyer

Contact name

Amjad Kazmi

Address

VICTORIA STREET
LONDON
SW1H 0EU
GB

Email

amjad.kazmi@dhsc.gov.uk